Neuraxis, INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.6M | $2.7M | $2.5M | — | $2.7M |
| Cost of revenue | $562,916 | $362,002 | $303,345 | — | $297,060 |
| Gross profit | $3.0M | $2.3M | $2.2M | — | $2.4M |
| Research and development | $493,611 | $433,614 | $169,315 | — | $225,610 |
| Operating income | -$7.8M | -$7.2M | -$6.7M | — | -$3.4M |
| Interest expense | $73,969 | $174,328 | $476,416 | — | $318,666 |
| Net income | -$7.8M | -$8.2M | -$14.6M | — | -$4.8M |
| Balance Sheet | |||||
| Cash and equivalents | $5.0M | $3.7M | $78,560 | $761,249 | $253,699 |
| Current assets | $5.7M | $4.3M | $242,610 | $966,854 | $476,957 |
| Total assets | $6.4M | $4.8M | $509,498 | $1.2M | $1.5M |
| Current liabilities | $2.8M | $2.4M | $1.9M | $2.3M | $7.0M |
| Total liabilities | $3.0M | $2.7M | $1.9M | $2.3M | $7.1M |
| Stockholders' equity | $3.4M | $2.1M | -$1.4M | -$1.1M | -$5.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.4M | -$6.1M | -$6.7M | — | -$2.3M |
| Depreciation and amortization | $37,691 | $37,831 | $40,725 | — | $37,133 |
| Stock-based compensation | $596,852 | $227,000 | — | — | $27,319 |
| Capital expenditure | $31,150 | $27,776 | $30,781 | — | $1,390 |
| Free cash flow | -$6.5M | -$6.1M | -$6.7M | — | -$2.3M |
| Impairments | $0 | $0 | — | — | — |
Shares outstanding 12.4M · Free float 52.3%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.